161 related articles for article (PubMed ID: 8532423)
1. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children.
Chang D
Pediatr Infect Dis J; 1995 Aug; 14(8):667-73. PubMed ID: 8532423
[TBL] [Abstract][Full Text] [Related]
2. A prospective study of vancomycin pharmacokinetics and dosage requirements in pediatric cancer patients.
Chang D; Liem L; Malogolowkin M
Pediatr Infect Dis J; 1994 Nov; 13(11):969-74. PubMed ID: 7845750
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics and dosing optimization of vancomycin in children with malignant hematological disease.
Zhao W; Zhang D; Fakhoury M; Fahd M; Duquesne F; Storme T; Baruchel A; Jacqz-Aigrain E
Antimicrob Agents Chemother; 2014 Jun; 58(6):3191-9. PubMed ID: 24663023
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.
Stockmann C; Sherwin CM; Zobell JT; Lubsch L; Young DC; Olson J; Noyes BE; Ampofo K; Spigarelli MG
Pharmacotherapy; 2013 Dec; 33(12):1288-96. PubMed ID: 23824677
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin pharmacokinetics in neonates and infants: a retrospective evaluation.
Asbury WH; Darsey EH; Rose WB; Murphy JE; Buffington DE; Capers CC
Ann Pharmacother; 1993 Apr; 27(4):490-6. PubMed ID: 8477127
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
Adane ED; Herald M; Koura F
Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
[TBL] [Abstract][Full Text] [Related]
7. The characteristics and impact indicator of vancomycin pharmacokinetics in cancer patients complicated with severe pneumonia.
Zhang X; Wang D
J Infect Chemother; 2020 May; 26(5):492-497. PubMed ID: 31983615
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin dosing in children and young adults: back to the drawing board.
Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
[TBL] [Abstract][Full Text] [Related]
9. Characterization of vancomycin pharmacokinetics in the adult acute myeloid leukemia population.
Jarkowski A; Forrest A; Sweeney RP; Tan W; Segal BH; Almyroudis N; Wang ES; Wetzler M
J Oncol Pharm Pract; 2012 Mar; 18(1):91-6. PubMed ID: 21521799
[TBL] [Abstract][Full Text] [Related]
10. Vancomycin population pharmacokinetics in neonates.
de Hoog M; Schoemaker RC; Mouton JW; van den Anker JN
Clin Pharmacol Ther; 2000 Apr; 67(4):360-7. PubMed ID: 10801244
[TBL] [Abstract][Full Text] [Related]
11. Vancomycin pharmacokinetics and dosing in premature neonates.
McDougal A; Ling EW; Levine M
Ther Drug Monit; 1995 Aug; 17(4):319-26. PubMed ID: 7482683
[TBL] [Abstract][Full Text] [Related]
12. Non steady state and steady state PKS Bayesian forecasting and vancomycin pharmacokinetics in ICU adult patients.
Polard E; Le Bouquin V; Le Corre P; Kérebel C; Trout H; Feuillu A; Le Verge R; Mallédant Y
Ther Drug Monit; 1999 Aug; 21(4):395-403. PubMed ID: 10442692
[TBL] [Abstract][Full Text] [Related]
13. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin dosing in neutropenic patients.
Haeseker MB; Croes S; Neef C; Bruggeman CA; Stolk LM; Verbon A
PLoS One; 2014; 9(11):e112008. PubMed ID: 25390637
[TBL] [Abstract][Full Text] [Related]
15. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures.
Pea F; Porreca L; Baraldo M; Furlanut M
J Antimicrob Chemother; 2000 Mar; 45(3):329-35. PubMed ID: 10702552
[TBL] [Abstract][Full Text] [Related]
16. A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population.
Lamarre P; Lebel D; Ducharme MP
Antimicrob Agents Chemother; 2000 Feb; 44(2):278-82. PubMed ID: 10639350
[TBL] [Abstract][Full Text] [Related]
17. Towards precision dosing of vancomycin: a systematic evaluation of pharmacometric models for Bayesian forecasting.
Broeker A; Nardecchia M; Klinker KP; Derendorf H; Day RO; Marriott DJ; Carland JE; Stocker SL; Wicha SG
Clin Microbiol Infect; 2019 Oct; 25(10):1286.e1-1286.e7. PubMed ID: 30872102
[TBL] [Abstract][Full Text] [Related]
18. Vancomycin serum concentrations in pediatric oncologic/hematologic intensive care patients.
Silva DC; Seixas GT; Araujo OR; Arduini RG; Carlesse FA; Petrilli AS
Braz J Infect Dis; 2012; 16(4):361-5. PubMed ID: 22846125
[TBL] [Abstract][Full Text] [Related]
19. Performance of Bayesian Area Under the Concentration-Time Curve-Based Pharmacokinetic Dosing Based on a One-Compartment Model and Trough-Only Monitoring for Vancomycin.
Salehpour N; Riley LD; Gonzales MJ; Kobic E; Nix DE
Antimicrob Agents Chemother; 2023 Jun; 67(6):e0017223. PubMed ID: 37133362
[TBL] [Abstract][Full Text] [Related]
20. Pilot Study of a Bayesian Approach To Estimate Vancomycin Exposure in Obese Patients with Limited Pharmacokinetic Sampling.
Carreno JJ; Lomaestro B; Tietjan J; Lodise TP
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28289024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
